← All trials
NCT04764630
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2021
- Primary completion
- Mar 20, 2021
- Completion date
- Mar 20, 2021
- First posted
- Feb 21, 2021
- Last posted
- Aug 23, 2021
- Enrollment
- 21
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Food and Drug AdministrationLead sponsor
- Spaulding Clinical Research Inc.Overall official - principal investigator
- Spaulding Clinical Research Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.